2023

• business2023/01/11

  Combined Clinical Trial Application of Cannabinoid CB2 Receptor Agonist AAT-730 for First-In-Human Clinical Trial has been submitted by Oxford Cannabinoid Technologies to UK Regulatory Agencies

  Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO：Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that a combined clinical trial application for AAT-730 (OCT461201) has been successfully submitted to UK Medicines & Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) on January 4th, 2023.

• science2023/01/11

  Ikena Oncology presented results of a clinical trial of grapiprant (AAT-007/IK-007) in patients with advanced microsatellite stable colorectal cancer

  Ikena Oncology presented results of a clinical trial of IK-007 in patients with advanced microsatellite stable colorectal cancer at ESMO Immuno-Oncology Annual Congress 2022. For details, please refer an abstract of the presentation at congress homepage.

• patent2023/01/06

  European Patent Office Grants AskAt EP4 Receptor Antagonist Use Patent for the Treatment of Cartilage Disease

  AskAt received a notice of the decision to grant a European patent pursuant to Article 97(1) EPC from the European Patent Office as of December 8, 2022. This grant of European Patent Application No. 14768803.0 (Filing Date: March 19, 2014), is an EP4 receptor antagonist use patent for the treatment of cartilage disease.